Further investigation is warranted to assess the impact of analytical workflow on real-world clinical samples in order to evaluate the critical points found in the MET exon 14 skipping analysis for selecting NSCLC patients for targeted therapy. The gene discussed is MET; the disease is non-small cell lung carcinoma.